Antiviral effects and mechanism of Qi pi pill against influenza viruses

Abstract

Background: Qi pi pill (QPP), which contains Renshen, Baizhu, Fuling, Gancao, Chenpi, Shanyao, Lianzi, Shanzha, Liushenqu, Maiya, and Zexie, was recommended for preventing and treating COVID-19 in Shandong Province (China). However, the mechanism by which QPP treats infectious diseases remains unclear. This study aims to investigate the therapeutic effect of QPP in vitro and on acute influenza infection in mice, exploring its mechanism of action against influenza A virus (IAV).

Methods: The in vitro activity of QPP was assessed using dose–response curve analysis and titer reduction assay, and its antiviral mechanism was identified in vitro by real-time polymerase chain reaction (PCR), time-of-addition, and enzymatic assays. The antiviral efficacy of QPP was further evaluated in vivo using BALB/c mice infected with IAV. At the same time, each single Chinese herbal medicine in QPP was evaluated to preliminarily identify those with antiviral effects.

Results: In vitro results showed that QPP exhibited a higher potency antiviral effect against both influenza A and B viruses, inhibiting viral RNA replication and release by targeting RNA-dependent RNA polymerase and neuraminidase. Additionally, QPP significantly decreased the expression of inflammatory cytokines in A549 cells. In vivo study revealed that QPP significantly reduced the lung index and viral load in lung tissue of mice infected with IAV. Renshen, Gancao, Zexie, and Lianzi were the Chinese herbal medicines from QPP that showed anti-IAV activity.

Conclusion: The antiviral activity of QPP targets IAV replication and release, cytokine modulation in host cells, and provides protection in mice with acute influenza infection.

Keywords

anti-inflammatory / Chinese patent medicine / influenza A virus / Qi pi pill / traditional Chinese medicine

References

[1] Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis. 2020; 39(7): 1201-1208.

[2] Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015; 17(3): 295-300.

[3] Hutchinson EC. Influenza Virus. Trends Microbiol. 2018; 26: 809-810.

[4] Bouvier NM, Palese P. The biology of influenza viruses. Vaccine. 2008; 26: D49-D53.

[5] Li Y, Huo S, Yin Z, et al. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. MBio. 2023; 14(5): e0127323.

[6] Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine for influenza a in children and the elderly. Cochrane Database Syst Rev. 2014; 2014(11): Cd002745.

[7] Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antivir Res. 2018; 160: 109-117.

[8] Loukotková L, Basavarajappa M, Lumen A, et al. Pharmacokinetics of oseltamivir phosphate and oseltamivir carboxylate in non-pregnant and pregnant rhesus monkeys. Regul Toxicol Pharmacol. 2020; 112: 104569.

[9] Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020; 209: 107512.

[10] Meseko C, Sanicas M, Asha K, Sulaiman L, Kumar B. Antiviral options and therapeutics against influenza: history, latest developments and future prospects. Front Cell Infect Microbiol. 2023; 13: 1269344.

[11] Wong DD, Choy KT, Chan RW, et al. Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation. J Virol. 2012; 86(19): 10558-10570.

[12] Samson M, Abed Y, Desrochers FM, et al. Characterization of drug-resistant influenza virus a(H1N1) and a(H3N2) variants selected in vitro with laninamivir. Antimicrob Agents Chemother. 2014; 58(9): 5220-5228.

[13] Goto T, Kawai N, Bando T, et al. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for a(H3N2) influenza: a multicenter study of the 2022-2023 season. Antivir Res. 2024; 224: 105853.

[14] Huang K, Zhang P, Zhang Z, et al. Traditional Chinese medicine (TCM) in the treatment of COVID-19 and other viral infections: efficacies and mechanisms. Pharmacol Ther. 2021; 225: 107843.

[15] Shan Z, Sun J, Li J, et al. Mechanism of Huashi Baidu prescription in treating influenza viral pneumonia based on transcriptome. Chin J Exp Tradit Med Formulae. 2023; 29(18): 54-61.

[16] Xu P, Yang Z, Du S, Hong Z, Zhong S. Intestinal microbiota analysis and network pharmacology reveal the mechanism by which Lianhua Qingwen capsule improves the immune function of mice infected with influenza a virus. Front Microbiol. 2022; 13: 1035941.

[17] Ma Y, Guo Y, Liu J, et al. Study on treatment of influenza a H1N1 induced severe pneumonia by Xuebijing injection. World Chin Med. 2015; 10(2): 243-246.

[18] Zhai X, Wang X, Wang L, Xiu L, Wang W, Pang X. Treating different diseases with the same method-a traditional Chinese medicine concept analyzed for its biological basis. Front Pharmacol. 2020; 11: 946.

[19] Flerlage T, Boyd DF, Meliopoulos V, Thomas PG, Schultz-Cherry S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat Rev Microbiol. 2021; 19(7): 425-441.

[20] Zhang C, Zhang G, Zhang Y, et al. Development of an HiBiT-tagged reporter H3N2 influenza a virus and its utility as an antiviral screening platform. J Med Virol. 2023; 95(1): e28345.

[21] Zhao X, Lin X, Li P, et al. Expanding the tolerance of segmented influenza a virus genome using a balance compensation strategy. PLoS Pathog. 2022; 18(8): e1010756.

[22] Li P, Ju H, Zhang Y, et al. Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses. J Med Virol. 2023; 95(7): e28968.

[23] Dong M, Wang Y, Li P, et al. Allopregnanolone targets nucleoprotein as a novel influenza virus inhibitor. Virol Sin. 2023; 38(6): 931-939.

[24] Li P, Du R, Chen Z, et al. Punicalagin is a neuraminidase inhibitor of influenza viruses. J Med Virol. 2021; 93(6): 3465-3472.

[25] Liu M, Zhao F, Xu J, et al. Qingjin Huatan decoction protects mice against influenza a virus pneumonia via the chemokine signaling pathways. J Ethnopharmacol. 2023; 317: 116745.

[26] Hu Y, Zhang J, Musharrafieh RG, Ma C, Hau R, Wang J. Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza a and B viruses. Antivir Res. 2017; 145: 103-113.

[27] Samji T. Influenza a: understanding the viral life cycle. Yale J Biol Med. 2009; 82(4): 153-159.

[28] Massari S, Desantis J, Nizi MG, Cecchetti V, Tabarrini O. Inhibition of influenza virus polymerase by interfering with its protein-protein interactions. ACS Infect Dis. 2021; 7(6): 1332-1350.

[29] Du R, Cui Q, Rong L. Competitive cooperation of hemagglutinin and neuraminidase during influenza a virus entry. Viruses. 2019; 11(5): 458.

[30] Wang Z, Fang J, Luo J, et al. Antiviral activity of 3D, a Butene lactone derivative against influenza a virus in vitro and in vivo. Viruses. 2021; 13(2): 278.

[31] Fukao K, Noshi T, Yamamoto A, et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza a virus infection. J Antimicrob Chemother. 2019; 74(3): 654-662.

[32] Sakai K, Ami Y, Nakajima N, et al. TMPRSS2 independency for haemagglutinin cleavage in vivo differentiates influenza B virus from influenza a virus. Sci Rep. 2016; 6: 29430.

[33] Liang Y. Pathogenicity and virulence of influenza. Virulence. 2023; 14(1): 2223057.

[34] Yang M, Wang Y, Yue Y, et al. Traditional Chinese medicines as effective agents against influenza virus-induced pneumonia. Biomed Pharmacother. 2022; 153: 113523.

[35] Ye Y, Wang H, Liu J, Zhao F, Xu P. Polygalasaponin F treats mice with pneumonia induced by influenza virus. Inflammopharmacology. 2020; 28(1): 299-310.

[36] Ding Y, Zeng L, Li R, et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17(1): 130.

[37] Zhao W, Liu Z, Zhang Z, et al. Si Jun Zi decoction inhibits the growth of lung cancer by reducing the expression of PD-L1 through TLR4/MyD88/NF-κB pathway. J Ethnopharmacol. 2024; 318: 116948.

[38] Han P, Wang Y. Effect of modified Sijunzi decoction on pulmonary function and inflammation indexes in children with ventilator-associated severe pneumonia. J Clin Med Pract. 2019; 23(3): 70-72.

[39] Im K, Kim J, Min H. Ginseng, the natural effectual antiviral: protective effects of Korean red ginseng against viral infection. J Ginseng Res. 2016; 40(4): 309-314.

[40] Yang X, Sun H, Zhang Z, et al. Antiviral effect of Ginsenosides rk1 against influenza a virus infection by targeting the hemagglutinin 1-mediated virus attachment. Int J Mol Sci. 2023; 24(5): 4967.

[41] Chen XX, Zhou HX, Qi WB, et al. Antiviral effects of the combination of glycyrrhizin and ribavirin against influenza a H1N1 virus infection in vivo. Yao Xue Xue Bao. 2015; 50(8): 966-972.

[42] Baltina LA, Zarubaev VV, Baltina LA, et al. Glycyrrhizic acid derivatives as influenza a/H1N1 virus inhibitors. Bioorg Med Chem Lett. 2015; 25(8): 1742-1746.

[43] Dao TT, Nguyen PH, Lee HS, et al. Chalcones as novel influenza a (H1N1) neuraminidase inhibitors from Glycyrrhiza inflata. Bioorg Med Chem Lett. 2011; 21(1): 294-298.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.